Published • loading... • Updated
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
The biopharmaceutical company will sell 10.6 million shares and grant underwriters a 30-day option for 1.6 million more.
Summary by Charleston Gazette-Mail
10 Articles
10 Articles
The Herald-Dispatch+8 Reposted by 8 other sources
Bambusa Therapeutics Announces Pricing of Upsized Initial Public Offering
BOSTON, Oct. 29, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Nasdaq: BBTX) ("Bambusa Therapeutics" or "Bambusa"), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, today announced the pricing of its upsized initial public offering of…
Coverage Details
Total News Sources10
Leaning Left2Leaning Right0Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 22%
C 78%
Factuality
To view factuality data please Upgrade to Premium
